Table 2.
Summary pooled HR (95% CI) for subgroup analyses of OS, PFS and CSS using random-effects models.
| Cancer site | OS | P value | PFS | P value | CSS | P value | |||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | HR | 95% CI | ||||
| breast | 0.77 | 0.69–0.86 | .000 | 0.64 | 0.44–0.91 | .013 | 0.84 | 0.73–0.96 | .009 |
| colorectal | 0.81 | 0.65–1.01 | .060 | 1.00 | 0.89–1.13 | .998 | 0.77 | 0.64–0.94 | .008 |
| endometrial | 0.65 | 0.44–0.97 | .034 | 0.73 | 0.37–1.45 | .371 | |||
| head and neck | 0.92 | 0.77–1.09 | .308 | 0.77 | 0.41–1.44 | .415 | |||
| hepatocellular | 0.75 | 0.58–0.97 | .027 | ||||||
| lung | 0.79 | 0.69–0.92 | .002 | 0.61 | 0.48–0.79 | .000 | |||
| ovarian | 0.61 | 0.32–1.16 | .131 | 0.37 | 0.25–0.55 | .000 | |||
| pancreatic | 0.80 | 0.67–0.95 | .011 | ||||||
| prostate | 0.94 | 0.87–1.02 | .141 | 1.01 | 0.80–1.28 | .941 | 0.83 | 0.70–0.98 | .030 |
| overall | 0.81 | 0.77–0.85 | .000 | 0.76 | 0.66–0.87 | .000 | 0.79 | 0.73–0.86 | .001 |
95%CI = 95% confidence interval, CSS = cancer-specific survival, HR = hazard ratio, OS = overall survival, PFS = progression-free survival.